STOCK TITAN

Paradigm BioCapital reports 10.4M-share stake in Erasca (NASDAQ: ERAS)

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
SCHEDULE 13G/A

Rhea-AI Filing Summary

Paradigm BioCapital and related reporting persons disclosed beneficial ownership positions in Erasca, Inc. common stock. Paradigm BioCapital Advisors LP/GP and Senai Asefaw report 10,392,702 shares (representing 3.3% of the class) as of the close of business on March 31, 2026. The filing shows Paradigm BioCapital International Fund Ltd. directly owns 9,157,687 shares (2.9%).

The percentages use a share base of 310,806,888 shares outstanding as of March 31, 2026, cited from the issuer's Form 10-Q filed May 11, 2026. Reporting persons disclaim ownership except for the shares they directly beneficially own; the Adviser is identified as investment manager of the Fund and related accounts.

Positive

  • None.

Negative

  • None.

Insights

Large institutional holder reports single-digit stakes across related entities.

The filing lists 10,392,702 shares (3.3%) held by Paradigm-related reporting persons and 9,157,687 shares (2.9%) held by the Fund, using March 31, 2026 as the time anchor. These positions are disclosed as direct beneficial ownership and are tied to the Adviser’s managed accounts.

Ownership disclosure is routine under Schedule 13G/A; cash-flow treatment or sale intentions are not stated in the excerpt. Subsequent filings or press releases would be required to reveal any active buying or selling intent.

Paradigm beneficially owned 10,392,702 shares reported as of March 31, 2026
Paradigm BioCapital International Fund Ltd. 9,157,687 shares reported as of March 31, 2026
Shares outstanding (used for percentages) 310,806,888 shares outstanding as of March 31, 2026 per issuer Form 10-Q
Beneficially own regulatory
"The Fund and one or more separately managed accounts managed by the Adviser directly beneficially own the Common Stock"
Beneficially own means having the economic rights and risks of a security—such as the right to receive dividends, sell the shares, or profit from price changes—whether or not your name appears on the official share register. Think of it like renting a car: you use it and reap the benefits even if the title lists someone else. Investors care because beneficial ownership determines who truly controls value, must be disclosed under securities rules, and can signal potential influence or trading activity that affects a stock’s price.
Sole Voting Power / Sole Dispositive Power regulatory
"Sole Voting Power 10,392,702.00 ... Sole Dispositive Power 10,392,702.00"
Schedule 13G/A regulatory
"This is filed by the following (the "Reporting Persons"): ..."
A Schedule 13G/A is an amended public filing with the U.S. securities regulator that updates a previous Schedule 13G, disclosing when an individual or group holds a substantial (typically over 5%) stake in a company and is claiming a passive, non‑controlling intent. Investors monitor these updates because rising or falling holdings can signal changing confidence, potential future moves, or shifts in voting power — like watching a public ledger where large shareholders quietly adjust their positions.





29479A108

(CUSIP Number)
03/31/2026

(Date of Event Which Requires Filing of this Statement)


Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
Rule 13d-1(b)
Rule 13d-1(c)
Rule 13d-1(d)




schemaVersion:


SCHEDULE 13G





SCHEDULE 13G




Comment for Type of Reporting Person: limited liability company


SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G



Paradigm BioCapital Advisors LP
Signature:/s/ David K. Kim
Name/Title:David K. Kim / Authorized Signatory
Date:05/15/2026
Paradigm BioCapital Advisors GP LLC
Signature:/s/ David K. Kim
Name/Title:David K. Kim / Authorized Signatory
Date:05/15/2026
Senai Asefaw, M.D.
Signature:/s/ Senai Asefaw, M.D.
Name/Title:N/A
Date:05/15/2026
Paradigm BioCapital International Fund Ltd.
Signature:/s/ David K. Kim
Name/Title:David K. Kim / Authorized Signatory
Date:05/15/2026

FAQ

What stake does Paradigm BioCapital report in ERAS?

Paradigm BioCapital Advisors and affiliated reporting persons report 10,392,702 shares, representing 3.3% of Erasca common stock as of March 31, 2026. The amount is shown on the cover-page ownership fields in the filing.

How many shares does Paradigm BioCapital International Fund Ltd. hold in ERAS?

The Fund is reported to directly own 9,157,687 shares, equal to 2.9% of the class as of March 31, 2026. This figure appears on the cover-page ownership line for the Fund.

What share count is used to calculate percentages in the filing?

Percentages are calculated using 310,806,888 shares outstanding as of March 31, 2026, cited from Erasca’s Form 10-Q filed with the SEC on May 11, 2026. That anchor is stated in Item 4(b) of the filing.

Does the filing state any planned sales or purchases by Paradigm?

No. The Schedule 13G/A excerpt discloses beneficial ownership only and does not state any intent to buy or sell shares. The filing limits itself to ownership amounts and managerial relationships.

Who controls the reported shares according to the filing?

The filing says the Adviser is investment manager of the Fund and accounts, the Adviser GP is general partner, and Senai Asefaw is managing member; these parties may be deemed beneficial owners of the Fund and accounts’ shares.